Schizophrenia | Treatment Algorithms: Claims Data Analysis | US | 2023
Schizophrenia is a psychiatric disease that usually requires long-term treatment. The primary goals of treatment are to reduce the frequency and severity of psychotic episodes, maintain the reduction in these symptoms over the long term, and improve patients’ functional capacity. Schizophrenia is a highly drug-treated condition that uses an array of medications, including atypical and typical antipsychotics, resulting in a complex treatment algorithm. Although this drug market is saturated with generic therapies, the need for longer-acting agents and more-effective drugs gives branded agents (e.g., Janssen’s Invega Trinza, Intra-Cellular Therapies’ Caplyta, Alkermes’s Lybalvi, AbbVie’s Vraylar) the opportunity to be incorporated into the treatment algorithm. Our Treatment Algorithms study provides national patient-level claims data to explore the use of key therapies in both newly diagnosed and recently treated patients, providing insight into the current treatment landscape for schizophrenia.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed schizophrenia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed patients?
- How have oral (e.g., Caplyta, Rexulti, Vraylar) and long-acting injectables (e.g., Abilify Maintena, Aristada, Invega Sustenna, Invega Trinza) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of schizophrenia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of schizophrenia patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Geography: United States.
Real world data: Longitudinal patient-level claims data analysis.
Key companies: AbbVie, Alkermes, Janssen, Indivior, Intra-Cellular Therapies, Lundbeck, Otsuka, Sumitomo Dainippon Pharma / Sunovion Pharmaceuticals, Noven Pharma.
Key drugs covered: Invega Sustenna, Invega Trinza, Invega Hafyera, Abilify Maintena, Aristada, Risperdal Consta, Latuda, Rexulti, Vraylar, Perseris, Caplyta, Lybalvi, Secuado, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, typical antipsychotics, other generics.
Key analysis provided
- Brand / therapy usage across longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
